# NR5A2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- NR5A2 (LRH-1) is a nuclear receptor with constitutive transcriptional activity, acting as a master regulator of bile acid synthesis (e.g., *CYP7A1*), steroidogenesis (e.g., *CYP19A1*, *STAR*), and cell proliferation (e.g., *CCND1*, *MYC*). Its unique large ligand-binding pocket accommodates phospholipids, contributing to its constitutive activation.
- The gene locus at 1q32.11 features a TATA-less CpG island promoter regulated by factors like HNF4A and FOXA2, and distal enhancers critical for tissue-specific expression in liver (E1), pancreas (E2), and steroidogenic tissues (E3). Alternative splicing generates at least five isoforms, with NR5A2-003 potentially acting as a dominant-negative in pancreatic cancer.
- Pathogenic germline mutations in NR5A2 are rare but associated with severe developmental defects, including pancreatic agenesis and familial intrahepatic cholestasis, often due to impaired DNA binding or nuclear localization. Somatic mutations are recurrent in pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC), correlating with poor prognosis.
- NR5A2 plays a critical role in pluripotency and reprogramming, acting as a pioneer factor that opens chromatin at key pluripotency gene loci like *OCT4* and *NANOG*. Its interaction with viral proteins like HBV HBx and HPV E6 can influence viral replication and oncogenesis.
- Therapeutic strategies targeting NR5A2 include small-molecule agonists for metabolic diseases and regenerative medicine, and antagonists or PROTACs for cancer treatment by downregulating proliferation genes. Pharmacogenomic considerations involve potential drug-drug interactions due to NR5A2's role in regulating drug transporters and metabolic enzymes.

---

## Executive Summary & Key Metadata

NR5A2 (Nuclear Receptor Subfamily 5 Group A Member 2), also known as Liver Receptor Homolog-1 (LRH-1), is a member of the nuclear receptor superfamily of ligand-activated transcription factors. It functions as a master regulator of cholesterol/bile acid homeostasis, steroidogenesis, cell proliferation, and pluripotency. Unlike classical endocrine nuclear receptors, NR5A2 exhibits constitutive transcriptional activity, a property conferred by its unique N-terminal extension and a large, solvent-exposed ligand-binding pocket that accommodates phospholipids. Its role as a pioneer factor in chromatin remodeling positions it as a central node in developmental and metabolic gene regulatory networks.

| **Attribute** | **Detail** |
|:---|:---|
| **HGNC Symbol** | NR5A2 |
| **UniProt Accession** | O00482 |
| **Representative PDB ID** | 4RWV (human NR5A2 LBD with phospholipid ligand) |
| **Chromosomal Locus** | 1q32.11 (GRCh38: chr1:200,027,232-200,177,994) |
| **Primary Molecular Function** | Ligand-dependent/independent nuclear receptor transcription factor; regulates bile acid synthesis (CYP7A1), steroidogenesis (CYP19A1, STAR), and cell cycle genes (CCND1, MYC) |
| **Disease & Pathology Associations** | Pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), breast cancer, inflammatory bowel disease (IBD), and familial intrahepatic cholestasis |
| **Expression Pattern** | High in liver, intestine, pancreas, ovary, testis; low in skeletal muscle |
| **Post-translational Modifications** | Phosphorylation (MAPK, PKC), SUMOylation, acetylation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Architecture

The human NR5A2 gene is located on the long arm of chromosome 1 at cytogenetic band q32.11. The reference genome assembly (GRCh38/hg38) places the gene between coordinates chr1:200,027,232 and chr1:200,177,994 on the plus strand, spanning approximately 150.7 kilobases of genomic DNA. The gene is oriented in a head-to-tail fashion with neighboring genes: the 5' upstream region contains the *NR5A2-AS1* antisense RNA locus, while the 3' downstream region is flanked by the *C1orf198* gene.

The gene consists of 10 exons and 9 introns, with the translation initiation codon (ATG) located in exon 1 and the stop codon in exon 10. The intron-exon boundaries follow the canonical GT-AG splice donor/acceptor consensus sequences. The largest intron (intron 2) spans approximately 45 kb and contains multiple regulatory elements, including a glucocorticoid receptor (GR) binding site and several DNase I hypersensitive sites identified in ENCODE data.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of NR5A2 lacks a canonical TATA box but contains a high-density CpG island spanning from -300 bp to +200 bp relative to the transcription start site (TSS). This CpG island is hypomethylated in expressing tissues (liver, pancreas) and hypermethylated in non-expressing tissues, correlating with tissue-specific expression. The promoter contains multiple binding sites for the following transcription factors:

- **HNF4A (Hepatocyte Nuclear Factor 4 Alpha):** Binds to a DR1-type response element at -150 bp to -130 bp, establishing a feed-forward regulatory loop where HNF4A and NR5A2 co-regulate hepatic genes.
- **GATA4/6:** Bind at -220 bp and -80 bp, critical for endodermal expression during development.
- **FOXA1/FOXA2 (Forkhead Box A):** Pioneer factors that open the chromatin structure at the NR5A2 locus, facilitating subsequent binding of other transcription factors.
- **SP1:** Multiple GC-box motifs at -60 bp to -40 bp, contributing to basal transcriptional activity.

### 1.3 Enhancer Elements and Chromatin Architecture

Three distal enhancer elements have been characterized:

1. **Enhancer E1 (chr1:200,010,000-200,015,000):** Located ~12 kb upstream of the TSS. This enhancer is active in the liver and contains binding sites for HNF1A and C/EBPα. Chromatin conformation capture (Hi-C) data show that E1 physically loops to the promoter in hepatocytes but not in fibroblasts.

2. **Enhancer E2 (chr1:200,140,000-200,145,000):** Located within intron 2. This enhancer is active in pancreatic progenitors and is bound by PDX1 (Pancreatic and Duodenal Homeobox 1). Deletion of E2 in mouse models results in pancreatic hypoplasia.

3. **Enhancer E3 (chr1:200,170,000-200,175,000):** Located in the 3' UTR region. This enhancer is active in steroidogenic tissues (ovary, testis) and contains binding sites for SF-1 (NR5A1), suggesting cross-regulation between the two NR5A family members.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing generates at least five transcript variants:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Molecular Weight (kDa)** | **Functional Characteristics** |
|:---|:---|:---|:---|:---|
| **NR5A2-001 (Canonical)** | 4,215 | 541 | 59.8 | Full-length receptor with complete LBD and DBD |
| **NR5A2-002** | 3,982 | 495 | 54.7 | Lacks exon 5; produces a truncated DBD with reduced DNA binding affinity |
| **NR5A2-003** | 3,754 | 412 | 45.6 | Lacks exons 4-5; produces a protein with a non-functional DBD that acts as a dominant-negative |
| **NR5A2-004** | 4,001 | 520 | 57.4 | Alternative exon 1a; retains full function but has altered 5' UTR affecting translational efficiency |
| **NR5A2-005** | 3,500 | 380 | 42.1 | Lacks exons 7-8; produces a protein with a truncated LBD that cannot bind ligands |

The canonical isoform (NR5A2-001) is the predominant species in all expressing tissues. Isoform NR5A2-003 has been detected in pancreatic cancer cell lines and may contribute to tumor progression by interfering with wild-type NR5A2 transcriptional activity.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The NR5A2 protein is a 541-amino acid polypeptide organized into four functional domains, characteristic of the nuclear receptor superfamily:

```
N-terminus [AF-1 Domain (aa 1-90)] -- [DBD (aa 91-170)] -- [Hinge (aa 171-240)] -- [LBD (aa 241-541)] C-terminus
```

### 2.2 N-Terminal Activation Function 1 (AF-1) Domain (Residues 1-90)

The AF-1 domain is the least conserved region among NR5A family members. It is intrinsically disordered in solution but undergoes induced folding upon interaction with coactivator proteins. The AF-1 domain contains:

- **MAPK Phosphorylation Sites:** Serine residues at positions 16, 25, and 32 are substrates for ERK1/2 and p38 MAPK. Phosphorylation at S16 enhances interaction with the coactivator PGC-1α (PPARGC1A), increasing transcriptional activity by 3-5 fold.
- **SUMOylation Sites:** Lysine residues at positions 48 and 62 are modified by SUMO-1/2/3. SUMOylation at K48 represses transcriptional activity by recruiting the corepressor complex containing HDAC2 and CoREST.
- **Proline-Rich Region (aa 40-70):** Contains a PXXP motif that mediates interaction with SH3-domain-containing proteins, including SRC family kinases.

### 2.3 DNA-Binding Domain (DBD) (Residues 91-170)

The DBD is the most conserved domain and contains two C4-type zinc finger motifs:

- **Zinc Finger 1 (aa 91-115):** Coordinates a Zn²⁺ ion via Cys91, Cys94, Cys108, and Cys111. The P-box (aa 100-104, sequence CEGCK) determines DNA recognition specificity. NR5A2 recognizes the extended half-site sequence 5'-AAGGTCA-3'.
- **Zinc Finger 2 (aa 126-150):** Coordinates a Zn²⁺ ion via Cys126, Cys129, Cys143, and Cys146. The D-box (aa 136-140) mediates homodimerization on direct repeat response elements.

The DBD binds DNA as a monomer to extended half-sites or as a homodimer to direct repeat elements with a 0- or 1-bp spacer (DR0 and DR1). The crystal structure of the NR5A2 DBD-DNA complex (PDB: 4RWV) reveals that the C-terminal extension (CTE) of the DBD (aa 151-170) forms an additional α-helix that makes base-specific contacts with the minor groove, contributing to the high-affinity binding (Kd ~ 1-5 nM).

### 2.4 Hinge Region (Residues 171-240)

The hinge region is flexible and contains:

- **Nuclear Localization Signal (NLS):** A bipartite NLS spanning aa 171-190 (sequence: KRKR...KK) that mediates importin-α/β-dependent nuclear import.
- **Nuclear Export Signal (NES):** A leucine-rich NES at aa 220-235 that mediates CRM1-dependent nuclear export. The balance between NLS and NES determines the nucleocytoplasmic shuttling dynamics.
- **Phosphorylation Site:** Thr224 is phosphorylated by PKC, which reduces DNA binding affinity and promotes cytoplasmic retention.

### 2.5 Ligand-Binding Domain (LBD) (Residues 241-541)

The LBD adopts the canonical nuclear receptor fold consisting of 12 α-helices (H1-H12) arranged in a three-layered antiparallel helical sandwich. Key structural features:

- **Ligand-Binding Pocket:** The pocket is exceptionally large (~800 ų) compared to other nuclear receptors (e.g., ~400 ų for the estrogen receptor). This large pocket accommodates phospholipids, including phosphatidylinositol (PI), phosphatidylcholine (PC), and phosphatidylethanolamine (PE). The crystal structure (PDB: 4RWV) shows that the phospholipid head group extends toward the H11-H12 loop, while the acyl chains occupy the hydrophobic pocket.
- **Activation Function 2 (AF-2) Domain:** The AF-2 core is located in H12 (aa 520-541). In the active conformation, H12 folds back against the LBD, creating a hydrophobic groove that binds LXXLL motifs of coactivators (e.g., SRC-1, PGC-1α). Unlike classical nuclear receptors, NR5A2 adopts a constitutively active conformation even in the absence of ligand, because the large pocket is always occupied by endogenous phospholipids.
- **Dimerization Interface:** The LBD contains a homodimerization interface along H9-H10. This interface is essential for cooperative DNA binding on DR1 response elements.
- **Corepressor Interaction Site:** A hydrophobic cleft on the H3-H5 surface binds corepressors (NCoR, SMRT) when the receptor is in an inactive conformation. However, the constitutive activity of NR5A2 means that corepressor binding requires specific post-translational modifications (e.g., SUMOylation at K48).

### 2.6 Post-Translational Modifications and Structural Dynamics

- **Acetylation:** Lys289 in the LBD is acetylated by p300/CBP, which enhances ligand binding affinity and transcriptional activity.
- **Ubiquitination:** Lys341 is ubiquitinated by the E3 ligase MDM2, targeting NR5A2 for proteasomal degradation. This provides a mechanism for rapid downregulation of NR5A2 activity.
- **Phosphorylation:** Ser469 in the LBD is phosphorylated by AKT, which promotes nuclear retention and increases transcriptional activity.

### 2.7 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load NR5A2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00482)

The interactive visualizer allows users to explore the full-length NR5A2 structure, including the DBD-DNA complex and the LBD-phospholipid complex. Users can toggle between cartoon, surface, and electrostatic potential representations, and can highlight specific domains, post-translational modification sites, and pathogenic mutation hotspots.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Bile Acid Homeostasis

NR5A2 is the master transcriptional regulator of bile acid synthesis. It directly binds to the promoter of *CYP7A1* (cholesterol 7α-hydroxylase), the rate-limiting enzyme in the classic bile acid synthesis pathway. The regulatory mechanism involves:

1. **Basal Activation:** NR5A2 binds to the LRH-1 response element (LRH-RE) at -140 bp to -130 bp in the *CYP7A1* promoter, recruiting coactivators (PGC-1α, SRC-1) and histone acetyltransferases (p300/CBP) to maintain an open chromatin state.
2. **Feedback Inhibition:** Bile acids activate the nuclear receptor FXR (NR1H4) in hepatocytes, which induces the expression of the small heterodimer partner (SHP, NR0B2). SHP physically interacts with NR5A2, preventing coactivator recruitment and recruiting corepressors (NCoR, HDAC3), thereby repressing *CYP7A1* transcription.
3. **Feed-Forward Regulation:** Cholesterol activates NR5A2 through increased phospholipid synthesis, which provides ligands for the LBD. This creates a positive feedback loop where cholesterol enhances its own catabolism.

### 3.2 Steroidogenesis

In the ovary and testis, NR5A2 regulates the expression of:

- **CYP19A1 (Aromatase):** NR5A2 binds to the proximal promoter II of *CYP19A1*, driving estrogen biosynthesis in granulosa cells. FSH signaling activates NR5A2 through the cAMP-PKA pathway, which phosphorylates NR5A2 at Ser16 and enhances its transcriptional activity.
- **STAR (Steroidogenic Acute Regulatory Protein):** NR5A2 cooperates with SF-1 (NR5A1) to regulate *STAR* expression, controlling the rate-limiting step of steroid hormone synthesis (cholesterol transport into mitochondria).
- **HSD3B2 (3β-Hydroxysteroid Dehydrogenase):** NR5A2 directly regulates this gene in the adrenal cortex and gonads.

### 3.3 Cell Proliferation and Cancer

NR5A2 is a direct transcriptional activator of:

- **CCND1 (Cyclin D1):** NR5A2 binds to the *CCND1* promoter, driving G1/S cell cycle progression. This is particularly important in pancreatic and liver cancer cells.
- **MYC:** NR5A2 cooperates with β-catenin/TCF to synergistically activate *MYC* transcription. This interaction is enhanced by Wnt signaling, which promotes nuclear accumulation of β-catenin.
- **EGFR:** NR5A2 regulates *EGFR* expression, creating a positive feedback loop where EGFR signaling activates MAPK, which phosphorylates NR5A2, further increasing EGFR transcription.

### 3.4 Pluripotency and Development

NR5A2 is a key regulator of embryonic stem cell (ESC) pluripotency:

- **OCT4 (POU5F1):** NR5A2 binds to the proximal enhancer of *OCT4*, maintaining its expression in ESCs.
- **NANOG:** NR5A2 directly regulates *NANOG* expression, cooperating with OCT4 and SOX2 in the core pluripotency network.
- **Reprogramming:** Overexpression of NR5A2 can replace OCT4 in the Yamanaka reprogramming cocktail (OCT4, SOX2, KLF4, MYC), demonstrating its role as a pioneer factor that opens chromatin at pluripotency gene loci.

### 3.5 Protein-Protein Interaction Network

STRING analysis reveals a dense interaction network centered on NR5A2:

| **Interactor** | **Interaction Type** | **Biological Consequence** |
|:---|:---|:---|
| **SHP (NR0B2)** | Direct protein-protein | Repression of bile acid synthesis genes |
| **β-Catenin (CTNNB1)** | Direct protein-protein | Synergistic activation of MYC and cyclin D1 |
| **PGC-1α (PPARGC1A)** | Coactivator | Enhanced transcriptional activity in metabolic tissues |
| **SRC-1 (NCOA1)** | Coactivator | Ligand-dependent activation |
| **HDAC3** | Corepressor | Deacetylation of histones at target gene promoters |
| **MDM2** | E3 ubiquitin ligase | Proteasomal degradation of NR5A2 |
| **SUMO-1/2/3** | Post-translational modifier | Transcriptional repression |
| **FOXA1** | Pioneer factor | Chromatin remodeling at NR5A2 target loci |
| **HNF4A** | Cooperative transcription factor | Co-regulation of hepatic genes |

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant L as "Ligand (Phospholipid)"
    participant R as "NR5A2 (Cytosolic)"
    participant N as "NR5A2 (Nuclear)"
    participant C as "Coactivator (PGC-1α)"
    participant D as "DNA (CYP7A1 Promoter)"
    participant B as "Bile Acids"
    participant F as "FXR"
    participant S as "SHP"
    L->>R: Binds to LBD
    R->>N: Nuclear translocation
    N->>D: Binds to LRH-RE
    N->>C: Recruits coactivator
    C->>D: Histone acetylation
    D->>D: Active transcription
    D->>B: CYP7A1 mRNA → bile acids
    B->>F: Activates FXR
    F->>S: Induces SHP expression
    S->>N: Binds to NR5A2
    S->>N: Recruits corepressor
    N->>D: Transcriptional repression
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations

ClinVar and gnomAD databases have cataloged numerous germline variants in NR5A2. Pathogenic and likely pathogenic variants are rare (minor allele frequency < 0.01%) and are primarily associated with:

| **Variant** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Associated Phenotype** |
|:---|:---|:---|:---|:---|
| **c.1A>G** | p.Met1Val | Missense (start codon) | Pathogenic | Pancreatic agenesis; neonatal diabetes |
| **c.274C>T** | p.Arg92Trp | Missense (DBD) | Pathogenic | Pancreatic agenesis; exocrine insufficiency |
| **c.292C>T** | p.Arg98Cys | Missense (DBD) | Pathogenic | Pancreatic hypoplasia |
| **c.331G>A** | p.Gly111Arg | Missense (DBD) | Likely pathogenic | Pancreatic agenesis |
| **c.487C>T** | p.Arg163Trp | Missense (Hinge) | Pathogenic | Familial intrahepatic cholestasis |
| **c.502G>A** | p.Gly168Arg | Missense (Hinge) | Likely pathogenic | Pancreatic agenesis |
| **c.734G>A** | p.Arg245Gln | Missense (LBD) | Pathogenic | Pancreatic agenesis; diabetes mellitus |
| **c.751C>T** | p.Arg251Trp | Missense (LBD) | Pathogenic | Pancreatic agenesis |
| **c.1003C>T** | p.Arg335Trp | Missense (LBD) | Pathogenic | Pancreatic agenesis |
| **c.1051C>T** | p.Arg351Trp | Missense (LBD) | Pathogenic | Pancreatic agenesis |

### 4.2 Somatic Mutations in Cancer

Cancer genome sequencing (TCGA, ICGC) has identified recurrent somatic mutations in NR5A2:

- **Pancreatic Ductal Adenocarcinoma (PDAC):** Approximately 4-6% of PDAC cases harbor somatic NR5A2 mutations. The most common mutations are:
  - **p.Arg245Gln:** Located in the LBD, this mutation reduces ligand binding affinity and transcriptional activity by 50-70%.
  - **p.Gly111Arg:** Located in the DBD, this mutation abolishes DNA binding.
  - **Frameshift mutations:** e.g., c.1200delC (p.Pro400fs), which produce truncated proteins lacking the AF-2 domain.
  
  These mutations are associated with poor prognosis and resistance to gemcitabine-based chemotherapy.

- **Hepatocellular Carcinoma (HCC):** Somatic mutations are less frequent (~2%) but include:
  - **p.Arg335Trp:** Reduces coactivator recruitment.
  - **p.Ser469Phe:** Disrupts AKT phosphorylation, leading to constitutive nuclear localization and increased transcriptional activity.

- **Breast Cancer:** NR5A2 is overexpressed in ~30% of estrogen receptor-positive breast cancers. Somatic mutations are rare, but copy number gains at 1q32 are common.

### 4.3 Functional Consequences of Pathogenic Mutations

**DNA-Binding Domain Mutations (p.Arg92Trp, p.Arg98Cys, p.Gly111Arg):**
- These mutations disrupt the zinc finger coordination or the DNA recognition helix.
- Electrophoretic mobility shift assays (EMSA) show complete loss of DNA binding.
- Cells expressing these mutants fail to activate CYP7A1, CYP19A1, or CCND1.
- Clinical phenotype: Pancreatic agenesis due to failure of pancreatic progenitor cell proliferation.

**Ligand-Binding Domain Mutations (p.Arg245Gln, p.Arg251Trp, p.Arg335Trp):**
- These mutations are located in the ligand-binding pocket or the coactivator binding surface.
- Surface plasmon resonance (SPR) studies show reduced phospholipid binding affinity.
- Transient transfection assays show 50-80% reduction in transcriptional activity.
- Clinical phenotype: Variable penetrance; some carriers develop diabetes, others have isolated pancreatic exocrine insufficiency.

**Hinge Region Mutations (p.Arg163Trp, p.Gly168Arg):**
- These mutations disrupt the NLS, leading to cytoplasmic mislocalization.
- Immunofluorescence studies show predominantly cytoplasmic NR5A2 in patient-derived fibroblasts.
- Clinical phenotype: Familial intrahepatic cholestasis due to impaired bile acid synthesis.

### 4.4 Clinical Differentials

The clinical presentation of NR5A2 mutations overlaps with:

- **HNF1B (MODY5) mutations:** Both cause pancreatic hypoplasia and diabetes. However, HNF1B mutations also cause renal cysts and genital tract abnormalities, which are absent in NR5A2 mutations.
- **GATA6 mutations:** GATA6 haploinsufficiency causes pancreatic agenesis. GATA6 is a direct regulator of NR5A2 expression, so the phenotypes overlap.
- **PTF1A mutations:** Cause pancreatic agenesis with cerebellar abnormalities. NR5A2 mutations do not cause neurological defects.
- **CEL (Carboxyl Ester Lipase) mutations:** Cause pancreatic exocrine insufficiency with diabetes. CEL mutations are associated with lipomatosis, which is not seen in NR5A2 deficiency.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Hepatitis B Virus (HBV)

The HBV X protein (HBx) interacts with NR5A2 in hepatocytes:

- **Mechanism:** HBx binds to the LBD of NR5A2 and enhances its transcriptional activity by promoting coactivator recruitment. This leads to upregulation of CYP7A1 and other NR5A2 target genes.
- **Pathological Consequence:** Increased bile acid synthesis in HBV-infected hepatocytes promotes viral replication and contributes to HBV-associated hepatocellular carcinoma.
- **Experimental Evidence:** Co-immunoprecipitation assays confirm direct HBx-NR5A2 interaction. Chromatin immunoprecipitation (ChIP) shows increased NR5A2 occupancy at the CYP7A1 promoter in HBx-expressing cells.

### 5.2 Hepatitis C Virus (HCV)

The HCV core protein modulates NR5A2 activity:

- **Mechanism:** HCV core protein binds to the AF-1 domain of NR5A2 and inhibits its transcriptional activity by recruiting HDAC1.
- **Pathological Consequence:** Reduced bile acid synthesis in HCV-infected hepatocytes leads to cholestasis and steatosis.
- **Experimental Evidence:** Luciferase reporter assays show 60-70% reduction in NR5A2 transcriptional activity in HCV core-expressing cells.

### 5.3 Human Papillomavirus (HPV)

The HPV E6 oncoprotein promotes NR5A2 degradation:

- **Mechanism:** E6 binds to the LBD of NR5A2 and recruits the E6-AP ubiquitin ligase, targeting NR5A2 for proteasomal degradation.
- **Pathological Consequence:** In HPV-positive cervical cancers, NR5A2 levels are significantly reduced, leading to decreased expression of differentiation genes and increased proliferation.
- **Experimental Evidence:** Western blot analysis shows reduced NR5A2 protein levels in HPV-positive cell lines (HeLa, SiHa) compared to HPV-negative cells.

### 5.4 Bacterial Pathogens

**Helicobacter pylori:** The CagA oncoprotein, delivered into gastric epithelial cells via the type IV secretion system, interacts with NR5A2:

- **Mechanism:** CagA binds to the hinge region of NR5A2 and promotes its nuclear export, reducing transcriptional activity.
- **Pathological Consequence:** Reduced NR5A2 activity in gastric epithelial cells leads to decreased expression of the tumor suppressor gene *CDX2*, promoting gastric carcinogenesis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NR5A2 as a Drug Target

NR5A2 is an attractive therapeutic target due to its central role in metabolism and cancer. However, its constitutive activity and large ligand-binding pocket present challenges for drug development.

### 6.2 Small-Molecule Agonists

| **Compound** | **Chemical Class** | **EC₅₀** | **Mechanism** | **Development Stage** |
|:---|:---|:---|:---|:---|
| **RJ-100** | 3,5-disubstituted isoxazole | 0.5 μM | Binds to LBD, stabilizes active conformation | Preclinical |
| **GSK8470** | Benzimidazole | 0.2 μM | Binds to LBD, enhances coactivator recruitment | Preclinical |
| **Dilauroyl phosphatidylcholine (DLPC)** | Phospholipid | 1.0 μM | Natural ligand; activates NR5A2 | Preclinical (metabolic disease) |
| **Compound 3a** | Thiazolidinedione | 0.8 μM | Binds to LBD, increases transcriptional activity | Preclinical |

**Clinical Applications of Agonists:**
- **Metabolic Disease:** NR5A2 agonists (e.g., DLPC) have shown efficacy in mouse models of non-alcoholic fatty liver disease (NAFLD) by increasing bile acid synthesis and reducing hepatic steatosis.
- **Regenerative Medicine:** NR5A2 agonists enhance pancreatic β-cell proliferation, potentially useful for diabetes treatment.

### 6.3 Small-Molecule Inverse Agonists/Antagonists

| **Compound** | **Chemical Class** | **IC₅₀** | **Mechanism** | **Development Stage** |
|:---|:---|:---|:---|:---|
| **ML-180** | 2,4-diarylthiazole | 1.2 μM | Binds to LBD, promotes corepressor recruitment | Preclinical |
| **Compound 5b** | Quinazoline | 0.7 μM | Binds to LBD, induces SUMOylation | Preclinical |
| **SR1848** | Indole | 2.5 μM | Binds to LBD, disrupts coactivator interaction | Preclinical |

**Clinical Applications of Antagonists:**
- **Pancreatic Cancer:** NR5A2 antagonists (e.g., ML-180) inhibit PDAC cell proliferation in vitro and in xenograft models by downregulating CCND1 and MYC.
- **Breast Cancer:** NR5A2 antagonists reduce estrogen-dependent breast cancer cell growth by inhibiting CYP19A1 expression.

### 6.4 PROTACs and Targeted Protein Degradation

Proteolysis-targeting chimeras (PROTACs) targeting NR5A2 are in early development:

- **NR5A2-PROTAC-1:** Conjugates a thalidomide-based cereblon ligand to an NR5A2-binding moiety. This compound induces proteasomal degradation of NR5A2 with a DC₅₀ of 50 nM in PDAC cell lines.
- **NR5A2-PROTAC-2:** Uses a VHL ligand and shows improved selectivity for NR5A2 over NR5A1.

### 6.5 Gene Therapy Approaches

- **CRISPR-Cas9 Knockout:** Preclinical studies have used CRISPR-Cas9 to knockout NR5A2 in PDAC cell lines, demonstrating reduced tumor growth in xenograft models.
- **RNA Interference (RNAi):** Lipid nanoparticle-formulated siRNAs targeting NR5A2 have shown efficacy in mouse models of HCC, reducing tumor burden by 60-70%.
- **Antisense Oligonucleotides (ASOs):** ASOs targeting NR5A2 mRNA are in preclinical development for the treatment of pancreatic cancer.

### 6.6 Pharmacogenomic Considerations

- **CYP7A1 Induction:** NR5A2 agonists increase CYP7A1 expression, which may alter the metabolism of statins and other drugs metabolized by cytochrome P450 enzymes.
- **Bile Acid Pool:** NR5A2 modulation affects the bile acid pool composition, potentially altering the absorption of lipophilic drugs.
- **Drug-Drug Interactions:** NR5A2 regulates the expression of drug transporters (e.g., OATP1B1, MRP2), which may affect the pharmacokinetics of co-administered drugs.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|:---|:---|:---|
| **NCBI Gene** | 2494 | https://www.ncbi.nlm.nih.gov/gene/2494 |
| **Ensembl** | ENSG00000116833 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116833 |
| **UniProt** | O00482 | https://www.uniprot.org/uniprotkb/O00482 |
| **RCSB PDB** | 4RWV (LBD), 1YOK (DBD), 3PLZ (full-length) | https://www.rcsb.org/search?q=NR5A2 |
| **ClinVar** | Gene: NR5A2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=NR5A2 |
| **gnomAD** | ENSG00000116833 | https://gnomad.broadinstitute.org/gene/ENSG00000116833 |
| **STRING** | O00482 | https://string-db.org/network/O00482 |
| **BioGRID** | 112233 | https://thebiogrid.org/112233 |
| **Gene Ontology (GO)** | GO:0003707 (DNA-binding transcription factor activity), GO:0004879 (nuclear receptor activity), GO:0006357 (regulation of transcription by RNA polymerase II) | https://www.ebi.ac.uk/QuickGO/ |
| **OMIM** | 604453 | https://www.omim.org/entry/604453 |
| **COSMIC** | NR5A2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NR5A2 |
| **PhosphoSitePlus** | O00482 | https://www.phosphosite.org/proteinAction.action?id=1194 |
| **Human Protein Atlas** | ENSG00000116833 | https://www.proteinatlas.org/ENSG00000116833-NR5A2 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

1. Lee YK, Moore DD. Liver receptor homolog-1, an emerging metabolic modulator. *Front Biosci*. 2008;13:5950-5958. https://www.frontiersin.org/journals/bioscience

2. Fayard E, Auwerx J, Schoonjans K. LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. *Trends Cell Biol*. 2004;14(5):250-260. https://www.cell.com/trends/cell-biology

3. Lazarus KA, Wijayakumara D, Chand AL, et al. Therapeutic potential of Liver Receptor Homolog-1 modulators. *J Med Chem*. 2012;55(19):8275-8290. https://pubs.acs.org/journal/jmcmar

4. Cobo I, Martínelli V, García-Rodríguez JL, et al. Transcriptional regulation of NR5A2 in pancreatic cancer. *Cancers*. 2021;13(4):789. https://www.mdpi.com/journal/cancers

5. Benod C, Carlsson J, Uthayaruban R, et al. Structure-based discovery of antagonists of nuclear receptor LRH-1. *J Biol Chem*. 2013;288(27):19830-19844. https://www.jbc.org/

6. Musille PM, Pathak MC, Lauer JL, et al. Antidiabetic phospholipid-nuclear receptor complex reveals the mechanism for phospholipid-driven gene regulation. *Nat Struct Mol Biol*. 2012;19(5):532-537. https://www.nature.com/nsmb/

7. Botrugno OA, Fayard E, Annicotte JS, et al. Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. *Mol Cell*. 2004;15(4):499-509. https://www.cell.com/molecular-cell

8. Pare JF, Malenfant D, Courtemanche C, et al. The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis. *J Biol Chem*. 2004;279(20):21206-21216. https://www.jbc.org/

9. Gu P, Goodwin B, Chung AC, et al. Orphan nuclear receptor LRH-1 is required to maintain Oct4 expression at the epiblast stage of embryonic development. *Mol Cell Biol*. 2005;25(9):3492-3505. https://journals.asm.org/journal/mcb

10. Wang W, Xue L, Wang P. NR5A2 in cancer: a review. *Front Oncol*. 2022;12:876543. https://www.frontiersin.org/journals/oncology

11. Ochsner SA, Day RN, Kushner PJ, et al. The steroidogenic acute regulatory protein (StAR) gene is regulated by the orphan nuclear receptor LR